Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M HORWITZ

Showing results (711-720 of 832) with videos related to

Pageof 84
Sort By:
Blood Advances|August 19, 2025
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell LymphomaSwaminathan P Iyer, Neha Mehta-Shah, Ranjana H Advani, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
European Urology|January 29, 2023
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised TrialLoren K Mell, Stephanie L Pugh, Christopher U Jones, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2016
Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancerSkyler Bryce Johnson, Pamela R Soulos, Timothy D Shafman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 TrialSeth A Rosenthal, Chen Hu, Oliver Sartor, et al.
Cytotherapy|November 22, 2015
Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy PerspectiveMassimo Dominici, Karen Nichols, Alok Srivastava, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
Advances in Radiation Oncology|April 20, 2026
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202Krishnan R Patel, Stephanie L Pugh, Jeffry P Simko, et al.
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Pageof 84

Showing results (711-720 of 832) with videos related to

Sort By:
Pageof 84
Blood Advances|August 19, 2025
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell LymphomaSwaminathan P Iyer, Neha Mehta-Shah, Ranjana H Advani, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
European Urology|January 29, 2023
Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised TrialLoren K Mell, Stephanie L Pugh, Christopher U Jones, et al.
International Journal of Radiation Oncology, Biology, Physics|January 2, 2023
Five-Year Patient-Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate CancerHimanshu R Lukka, Snehal Deshmukh, Deborah W Bruner, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 29, 2016
Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancerSkyler Bryce Johnson, Pamela R Soulos, Timothy D Shafman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2019
Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 TrialSeth A Rosenthal, Chen Hu, Oliver Sartor, et al.
Cytotherapy|November 22, 2015
Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy PerspectiveMassimo Dominici, Karen Nichols, Alok Srivastava, et al.
The Lancet. Haematology|February 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell ProjectChristopher P Fox, Monica Civallero, Young-Hyeh Ko, et al.
Advances in Radiation Oncology|April 20, 2026
The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202Krishnan R Patel, Stephanie L Pugh, Jeffry P Simko, et al.
Blood|July 31, 2020
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab eraSabela Bobillo, Erel Joffe, Jessica A Lavery, et al.
Pageof 84